Clinical Study

Postmastectomy Radiotherapy for Locally Advanced Breast Cancer Receiving Neoadjuvant Chemotherapy

Icro Meattini,1 Sara Cecchini,1 Vanessa Di Cataldo,1 Calogero Saieva,2 Giulio Francolini,1 Vieri Scotti,1 Pierluigi Bonomo,1 Monica Mangoni,1 Daniela Greto,1 Jacopo Nori,3 Lorenzo Orzalesi,4 Donato Casella,4 Roberta Simoncini,4 Massimiliano Fambrini,5 Simonetta Bianchi,6 and Lorenzo Livi1

1 Department of Radiation-Oncology, University of Florence, Largo G. A. Brambilla 3, 50134 Florence, Italy
2 Molecular and Nutritional Epidemiology Unit, ISPO (Cancer Research and Prevention Institute), University of Florence, Largo G. A. Brambilla 3, 50134 Florence, Italy
3 Diagnostic Senology Unit, University of Florence, Largo G. A. Brambilla 3, 50134 Florence, Italy
4 Department of Surgery, University of Florence, Largo G. A. Brambilla 3, 50134 Florence, Italy
5 Department of Gynecology and Obstetrics, University of Florence, Largo G. A. Brambilla 3, 50134 Florence, Italy
6 Department of Pathology, University of Florence, Largo G. A. Brambilla 3, 50134 Florence, Italy

Correspondence should be addressed to Icro Meattini; icro.meattini@unifi.it

Received 27 February 2014; Revised 7 May 2014; Accepted 21 May 2014; Published 22 June 2014

Academic Editor: An Liu

Copyright © 2014 Icro Meattini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Neoadjuvant chemotherapy (NAC) is widely used in locally advanced breast cancer (BC) treatment. The role of postmastectomy radiotherapy (PMRT) after NAC is strongly debated. The aim of our analysis was to identify major prognostic factors in a single-center series, with emphasis on PMRT. From 1997 to 2011, 170 patients were treated with NAC and mastectomy at our center; 98 cases (57.6%) underwent PMRT and 72 cases (42.4%) did not receive radiation. At a median follow-up period of 7.7 years (range 2–16) for the whole cohort, median time to locoregional recurrence (LRR) was 3.3 years (range 0.7–12.4). The 5-year and 10-year actuarial LRR rate were 14.5% and 15.9%, respectively. At the multivariate analysis the factors that significantly correlated with survival outcome were ≥4 positive nodes (HR 5.0, 1.51–16.52; \( P = 0.035 \)), extracapsular extension (HR 2.18, 1.37–3.46; \( P = 0.009 \)), and estrogen receptor positive disease (HR 0.57, 0.36–0.90; \( P = 0.003 \)). Concerning LRR according to use of radiation, PMRT reduced LRR for patient with clinical T3 staged disease (\( P = 0.015 \)). Our experience confirmed the impact of pathological nodal involvement on survival outcome. PMRT was found to improve local control in patients presenting with clinical T3 tumors, regardless of the response to chemotherapy.

1. Introduction

Neoadjuvant chemotherapy (NAC) is widely used in locally advanced breast cancer (BC) treatment. It is increasingly used in women with early stage disease [1]. It allows the clinicians to observe tumor response and modify radiotherapy plan [2]. Adjuvant therapeutic strategies for patients who underwent NAC do not differ substantially from patients treated with upfront surgery [3–6]; nevertheless, the role of postmastectomy radiotherapy (PMRT) after NAC is strongly debated. Moreover there is a lack of prospective trials in this treatment setting.

In an era of “tailored treatment,” additional data are needed for patients who receive this treatment sequence to determine which subsets of patients can benefit from radiation [7].

The aim of our analysis was to identify major prognostic factors in a single-center series of advanced BC patients receiving NAC, with emphasis on the role of PMRT.

2. Materials and Methods

2.1. Patient Population. From 1997 to 2011, 226 patients were treated with NAC and mastectomy at the University of
Florence Radiotherapy Unit (Florence, Italy). Previous solid tumors, age less than 18, and BC recurrences or contralateral tumor were considered exclusion criteria of the study. To minimize bias, all patients with disease recurrence within 2 months after surgery, completion of adjuvant chemotherapy, and a minimum follow-up period shorter than 6 months were excluded from analysis. We retrospectively reviewed a series of 170 BC patients who received NAC and mastectomy; 98 cases (57.6%) underwent PMRT and 72 cases (42.4%) did not receive radiation. Informed consent was obtained from all patients.

In our multidisciplinary team, specialized expert pathologists, dedicated to BC specimens’ evaluation, perform pathology assessment. Estrogen receptor (ER) status, progesterone receptor (PgR) status, and Ki-67 labeling index determined with the MIB1 monoclonal antibody were assessed. For receptor (PgR) status, and Ki-67 labeling index determined by FISH. The applied well-validated [9] primary antibodies for ER and PgR status two categories (negative/positive) were assessed. For HER2 immunohistochemistry (IHC) scores of 0 and 1+ were considered negative. HER2 IHC 3+ and fluorescent in situ hybridization (FISH)—amplified tumors, were considered positive. All IHC 2+ tumors were tested for gene amplification by FISH. The applied well-validated [9] primary antibodies for evaluating ER and PgR in BC by IHC have been extensively described in earlier published reports [10, 11].

BC was classified according to the histological type and the AJCC TNM classification of malignant tumors. Concerning Ki-67, we used a validated [12] cut-off value of 20% to distinguish Ki-67 high from Ki-67 low, although the ideal threshold has not been identified yet and varies widely from 1 to 28.6% [13].

### 2.2. Treatment Details

All patients, except 8 cases, received anthracyclines as part of a combination chemotherapy regimen (98.8%), with 69 patients (40.6%) also receiving a taxane. Concerning HER2 status, 23 patients had HER2 positive and 45 patients had HER2 negative status at pathological specimen; in 102 cases HER2 status was undetermined or missing. None of these patients were treated with neoadjuvant or adjuvant trastuzumab, since they were treated before 2006.

Most commonly administered chemotherapy regimens were FEC and ET; FEC chemotherapy consisted of 500 mg/m$^2$ 5-fluorouracil, 75 mg/m$^2$ epirubicin, and 500 mg/m$^2$ cyclophosphamide, given on day 1. The ET regimen consisted of 75 mg/m$^2$ epirubicin and 75 mg/m$^2$ docetaxel, given on day 1. The median number of chemotherapy cycles received was 4 (mean, 4.7; range, 2–6).

Additionally, 108 patients (88.2%) received adjuvant hormonal therapy: tamoxifen for 5 years ($n = 63$; 37.1%), aromatase inhibitors for 5 years ($n = 52$; 30.6%), and tamoxifen for 2 years and then shift to aromatase inhibitors ($n = 35$; 20.5%).

Concerning PMRT, the treatment volumes typically included the chest wall and draining lymphatics ($n = 84$; 85.7%), consisting in the supravaculicular (SCV) and infraclavicular (ICV) nodal region (total dose 50 Gy; 2 Gy daily fractions), with mixed photon and electron beams technique, chosen at physician discretion. In our Institute we did not irradiate mammary internal nodal region, unless pathologically involved. In selected cases ($n = 14$; 14.3%) only chest wall was irradiated.

Patients underwent a treatment-planning noncontrast CT scan. Concerning CTV identification, for chest wall volume, the cranial limit was the caudal border of the clavicular head, the caudal limit was the contralateral inframammary fold, the lateral limit was the midaxillary line, and the medial limit was the stern-rib junction. For SCV nodes the cranial limit was a line passing below the cricoid cartilage, the caudal limit was the caudal edge of the clavicular head, the anterior limit was the poster edge of the sternocleidomastoid (SCM) muscle, the posterior limit was the anterior aspect of the scale muscle, the lateral limit was the lateral edge of the SCM muscle cranially, and the junction first rib-clavicle caudally, and the medial limit was a line excluding thyroid and trachea. For ICV nodes, the cranial limit was pectoralis minor muscle insert on coracoid, the caudal limit was axillary vessels cross-medial edge of pectoralis minor muscle, the anterior limit was the posterior surface of pectoralis major muscle, the posterior limit was ribs and intercostal muscles, the lateral limit was the medial border of pectoralis minor muscle, and the medial limit was the thoracic inlet.

### 2.3. Statistical Analysis

For the survival analysis, the date of histological BC diagnosis was used as the start of observation. The survival time was calculated from the date of diagnosis to the date of death or the date of the last follow-up for living patients. We considered as events the deaths for all causes (overall survival, OS). We also estimated the disease-free survival (DFS) as the interval time from the date of diagnosis to the date of locoregional recurrence (LRR) or distant metastases (DM).

The actuarial rates of death, LRR, or DM were calculated according to the Kaplan-Meier method, and comparisons were made using the log-rank test. Estimated relative risk of death, LRR, or DM were expressed as hazard ratios (HR) and their corresponding 95% confidence intervals (95% CI).

The clinical and pathologic factors that were statistically significant (two-tailed $P < 0.05$) on univariate analysis of LRR, DM, or OS were included in a multivariate analysis using the Cox proportional hazards regression model. All statistical tests were performed by the SAS software (SAS for Windows, version 9.1).

In order to analyze if the concomitant presence of well-known [14] risk factors influences the LRR rate, we stratified the patients in three risk groups (0-1 factors versus 2 factors versus 3–5 factors). We considered the following risk features: skin/nipple involvement, SCV nodal involvement, no tamoxifen use, extracapsular extension (ECE), and ER negative disease.

### 3. Results

#### 3.1. Series Characteristics

The median age at BC diagnosis was 48.9 years (range 24–76). The median follow-up periods of all irradiated and nonirradiated cases were 7.2 and 6.7 years, respectively.
Table 1 showed major clinical characteristics of the whole series and stratified by radiation treatment. When compared with patients who did not receive PMRT, a larger number of irradiated patients had greater clinical and pathological T, N, and combined AJCC TNM stage ($P \leq 0.024$ for all comparisons). There were no differences between the two groups considering age, histology, nuclear grade, lymph vascular invasion (LVI), downstaging after NAC based on pathological response, use of hormonal therapy, Ki-67 index, and percentage of ER and PgR.

3.2. Prognostic Factors of the Whole Series. At a median follow-up period of 7.7 years (range 2–16; standard deviation (SD) 5.1), 98 patients are alive (57.6%) and 72 patients are dead (42.4%). Median time to LRR ($n = 26$) was 3.3 years (range 0.7–14.6; SD 3.9); median time to DM ($n = 86$) was 3.0 years (range 0.7–12.4; SD 2.6). The 5-year and 10-year actuarial LRR rate were 14.5% and 15.9%, respectively. The majority of LRR failures occurred on the chest wall ($n = 15$; 57.7%). SCV was the first nodal site of relapse in 7 cases (26.9%). Axillary ($n = 2$), infraclavicular ($n = 1$), and internal mammary nodal regions ($n = 1$) were rare sites of LRR (15.4%).

Table 2 showed LRR, DM, and OS rates according to main clinical features. In Table 3 survival rates were summarized according to major pathologic characteristics.

The factors that significantly correlated with poor LRR outcome were clinical N2 tumors, pathologic skin involvement, LVI, and the presence of ECE. The factors that significantly correlated with poor DM outcome were clinical N2 tumors, pN2, pN3 tumors, LVI, and ECE. Concerning OS, the significant protective features were pT1 tumors and ER positive status, while pN1, pN2, pN3 tumors, and ECE were unfavorable risk factors.

In the multivariate Cox regression analysis no factors were independently associated with LRR. The multivariate analysis of distant metastases occurrence and overall survival are described in Table 4. The factors that significantly correlated with survival outcome were ≥4 positive nodes, ECE, and estrogen receptor positive disease.

The LRR rate for the 61 patients (35.9%) with one or none of selected [14] risk factors (6 events) was 10.9%, the 75 patients (44.1%) with two factors (10 events) had a rate of 24.5%, and the 34 patients (20%) with three or more factors (10 events) had a rate of 54.3% (log rank test $P = 0.023$; Figure 1). In an analysis stratified by radiation use, PMRT showed a protective effect ($P = 0.029$).

3.3. Locoregional Recurrence Rate according to Use of Postmastectomy Radiotherapy. In Table 5 the impact of PMRT on LRR for various subgroups of patients is shown. PMRT was associated with reduced LRR for patient with clinical T3 staged disease (16.7% versus 38.7%; $P = 0.015$; Figure 2). For patients with clinical T4 and clinical N2 and N3 tumors, no difference in LRR rates was observed. Also concerning pathological features, no difference in LRR rates was observed. In addition, in the subset of patients that achieved complete response after NAC (pCR; $P = 0.29$) or downstaging ($P = 0.68$), no statistical significance was evidenced.

3.4. Treatment Safety. Major hematological and nonhematological side effects are summarized in Table 6. The most
Table 1: Distribution of 170 breast cancer cases according to adjuvant radiotherapy.

| Feature                     | Total 170 | No PMRT n = 72 | PMRT n = 98 | P value* |
|-----------------------------|-----------|----------------|-------------|----------|
| **Age groups**              |           |                |             |          |
| ≤40                         | 33        | 18             | 15          |          |
| 41–50                       | 62        | 25             | 37          |          |
| 51–60                       | 5         | 18             | 32          |          |
| >60                         | 25        | 11             | 14          | 0.40     |
| **Clinical T classification**|          |                |             |          |
| T1                          | 4         | 2              | 2           |          |
| T2                          | 52        | 28             | 24          |          |
| T3                          | 48        | 27             | 21          |          |
| T4                          | 66        | 15             | 51          |          |
| **Clinical N classification**|          |                |             |          |
| N0                          | 42        | 20             | 22          |          |
| N1                          | 95        | 45             | 50          |          |
| N2                          | 33        | 7              | 25          |          |
| **Clinical stage**          |           |                |             |          |
| IIA                         | 16        | 8              | 8           |          |
| IIB                         | 51        | 32             | 19          |          |
| IIIA                        | 35        | 17             | 18          |          |
| IIIB                        | 63        | 15             | 48          |          |
| IIIC                        | 3         | —              | 5           |          |
| **Multiple Foci**           |           |                |             |          |
| No                          | 99        | 50             | 49          |          |
| Yes                         | 71        | 2              | 49          |          |
| **Pathologic T classification**|          |                |             |          |
| pTx/pTis                    | 14        | 7              | 7           |          |
| pT1                         | 26        | 13             | 13          |          |
| pT2                         | 75        | 39             | 36          |          |
| pT3                         | 18        | 7              | 11          |          |
| pT4                         | 37        | 6              | 31          |          |
| **Pathologic N classification**|          |                |             |          |
| pN0                         | 20        | 14             | 6           |          |
| pN1                         | 63        | 29             | 34          |          |
| pN2                         | 52        | 16             | 36          |          |
| pN3                         | 35        | 13             | 22          |          |
| **Downstage**               |           |                |             |          |
| No                          | 115       | 43             | 72          |          |
| Yes                         | 55        | 29             | 26          | 0.07     |
| **Histology**               |           |                |             |          |
| Ductal invasive             | 118       | 55             | 63          |          |
| Lobular invasive            | 36        | 12             | 24          |          |
| Others                      | 16        | 5              | 11          | 0.24     |
| **Pathologic skin involvement**|          |                |             |          |
| Absent                      | 136       | 66             | 70          |          |
| Present                     | 34        | 6              | 28          | 0.001    |
| **Extracapsular extension** |           |                |             |          |
| Absent                      | 115       | 52             | 63          |          |
| Present                     | 55        | 20             | 35          | 0.32     |
| Feature                              | Total | No PMRT | PMRT | P value |
|-------------------------------------|-------|---------|------|---------|
|                                    | n = 170 | n = 72  | n = 98 |         |
| **LVI**                             |        |         |      |         |
| Absent                              | 101    | 47      | 54   | 0.21    |
| Present                             | 69     | 25      | 44   |         |
| **Nuclear grading**                 |        |         |      |         |
| G1                                  | 11     | 6       | 5    |         |
| G2                                  | 54     | 26      | 28   |         |
| G3                                  | 80     | 33      | 47   |         |
| **Ki 67 index**                     |        |         |      |         |
| <20                                 | 117    | 53      | 64   |         |
| ≥20                                 | 53     | 19      | 34   | 0.32    |
| **ER status**                       |        |         |      |         |
| Negative                            | 64     | 30      | 34   | 0.42    |
| Positive                            | 106    | 42      | 64   |         |
| **PgR status**                      |        |         |      |         |
| Negative                            | 83     | 40      | 43   | 0.16    |
| Positive                            | 87     | 32      | 55   |         |
| **NAC regimen**                     |        |         |      |         |
| Anthracyclines-based                | 69     | 27      | 42   |         |
| Anthracyclines and taxanes-based    | 93     | 44      | 49   |         |
| No anthracyclines                   | 8      | 1       | 7    | 0.13    |
| **Adjuvant hormonal therapy**       |        |         |      |         |
| No                                  | 62     | 28      | 34   |         |
| Tamoxifen                           | 75     | 31      | 44   |         |
| AIs                                 | 33     | 13      | 20   | 0.89    |

*Some data are missing; \( ^\circ \) P value from Fisher exact test or chi-square for trend, as appropriate.

PMRT: postmastectomy radiotherapy; LVI: lymphovascular invasion; ER: estrogen receptors; PgR: progesterone receptors; NAC: neoadjuvant chemotherapy; AIs: aromatase inhibitors.

represented hematological G3–G5 side effect was neutropenia (17%). The most frequent radiotherapy-related acute side effect was erythema (33%). At a median follow-up of 7.2 years, the most represented late RT-related side effect was fibrosis (20%).

### 4. Discussion

The Danish and the British Columbia trials have established the survival advantage following radiotherapy in postmastectomy patients [15, 16]. The Early Breast Cancer Trialists’ Collaborative Group meta-analysis has demonstrated that PMRT, besides improving local control rates, confers an OS benefit [17]. On the basis of these studies and others, the role of the indication to PMRT has traditionally been determined by pathologic staging, with surgery as the first treatment modality [18, 19].

NAC is nowadays based on regimens containing anthracyclines, taxanes, and trastuzumab in case of HER2 positive disease. The toxicity profile of these drugs is well known, namely, characterized by potential cardiac [20–23] and pulmonary [24–26] adverse events. Although NAC has many advantages, its impact on surgical staging reduces the applicability of the traditional pathologic guidelines for PMRT.

Guidelines for the use of PMRT after NAC have not been established. Retrospective series have demonstrated that the omission of PMRT after NAC in high-risk patients can result in an unacceptable high rate of LRR, even in case of pathological complete response [7, 27]. For this reason, the role of PMRT is generally determined by clinical staging before NAC without regard for the response to NAC [18].

Risk factors for LRR in this specific setting are not well established. Advanced clinical or pathologic stage, triple-negative receptor status, and presence of LVI and/or ECE emerged as high-risk features that should warrant consideration of PMRT after NAC [28]. In our experience greater clinical nodal status, tumor stage, the presence of LVI, and nodal ECE emerged as adverse prognostic factors; these results are in line with many published series [7, 18, 28, 29].

Concerning age at diagnosis, Garg et al. [30] retrospectively analyzed 107 consecutive BC patients younger than 35 years with stage IIA–IIIC disease, treated with doxorubicin-based NAC and mastectomy, with or without PMRT. In this
Table 2: Locoregional recurrence, distant metastases, and overall survival rates according to clinical factors.

| Variable                  | Patient | Overall survival | LRR free survival | DM free survival |
|---------------------------|---------|------------------|-------------------|------------------|
|                           |         | Deaths | $P$ value | LRR | $P$ value | DM | $P$ value |
| Age groups                |         |         |           |     |           |    |           |
| $\leq 40$                 | 33      | 16     | 6        | 20  | 20        | 20 |
| 41–50                     | 62      | 24     | 9        | 20  | 20        | 20 |
| 51–60                     | 5       | 20     | 9        | 25  | 25        | 25 |
| $>60$                     | 25      | 12     | 0.73     | 2   | 0.74      | 13 | 0.67      |
| Clinical T                |         |         |           |     |           |    |           |
| T1                        | 4       | 3      | 0        | 3   | 3         | 3  |
| T2                        | 52      | 15     | 3        | 18  | 18        | 18 |
| T3                        | 48      | 17     | 9        | 25  | 25        | 25 |
| T4                        | 66      | 37     | 0.09     | 14  | 0.28      | 40 | 0.12      |
| Clinical N                |         |         |           |     |           |    |           |
| N0                        | 42      | 14     | 5        | 15  | 15        | 15 |
| N1                        | 95      | 39     | 11       | 49  | 49        | 49 |
| N2                        | 33      | 19     | 0.15     | 10  | 0.034     | 22 | 0.028     |
| Clinical stage            |         |         |           |     |           |    |           |
| IIA                       | 16      | 5      | 0        | 5   | 5         | 5  |
| IIB                       | 51      | 17     | 6        | 21  | 21        | 21 |
| IIIA                      | 35      | 13     | 6        | 20  | 20        | 20 |
| IIIB                      | 63      | 36     | 14       | 39  | 39        | 39 |
| IIIC                      | 3       | 1      | 0.15     | 0   | 0.19      | 1  | 0.09      |
| Multiple Foci             |         |         |           |     |           |    |           |
| No                        | 99      | 40     | 18       | 46  | 46        | 46 |
| Yes                       | 71      | 32     | 0.60     | 8   | 0.28      | 40 | 0.19      |
| Downstage                 |         |         |           |     |           |    |           |
| No                        | 115     | 50     | 19       | 64  | 64        | 64 |
| Yes                       | 55      | 22     | 0.34     | 7   | 0.31      | 22 | 0.029     |
| PMRT                      |         |         |           |     |           |    |           |
| No                        | 72      | 31     | 12       | 36  | 36        | 36 |
| Yes                       | 98      | 41     | 0.83     | 14  | 0.57      | 50 | 0.93      |
| PMRT volumes              |         |         |           |     |           |    |           |
| Chest wall                | 14      | 5      | 1        | 5   | 5         | 5  |
| Chest wall + SC           | 74      | 34     | 0.35     | 12  | 0.38      | 43 | 0.11      |
| NAC regimen               |         |         |           |     |           |    |           |
| Anthracyclines-based      | 69      | 35     | 14       | 41  | 41        | 41 |
| Anthracyclines- and taxanes-based | 93 | 33 | 10 | 41 |
| No anthracyclines         | 8       | 4      | 0.25     | 2   | 0.29      | 4  | 0.16      |
| Adjuvant hormonal therapy |         |         |           |     |           |    |           |
| No                        | 62      | 34     | 10       | 35  | 35        | 35 |
| Tamoxifen                 | 75      | 28     | 11       | 34  | 34        | 34 |
| AIs                       | 33      | 10     | 0.11     | 5   | 0.93      | 17 | 0.31      |
| Total                     | 170     | 72     | 26       | 86  | 86        | 86 |

LRR: locoregional recurrence; DM: distant metastases; PMRT: postmastectomy radiotherapy; NAC: neoadjuvant chemotherapy; SC: supraclavicular nodal region; AIs: aromatase inhibitors.

experience the use of PMRT led to a statistically greater rate of local control and OS compared with patients without PMRT.

Response to NAC is another debated issue in adjuvant PMRT decision-making. Data regarding LRR rates in patients who achieve a pCR are limited, although few data supported stage IIA patients with pCR as being at low risk [28]. Concerning tumor biology and chemotherapy response, many experiences showed that residual disease after NAC seems to have a greater implication for outcome for those in whom systemic therapy would have been expected to produce a more favorable response, such as ER and HER2 positive patients [31–34]. Conversely, other studies suggested how PMRT should be indicated regardless of response to NAC [18, 35]. Also in
| Variable                        | Patient | Overall survival | LRR free survival | DM free survival |
|--------------------------------|---------|------------------|-------------------|------------------|
|                                |         | Deaths | P value | LRR | P value | DM | P value |
| Multiple foci                  |         |        |         |     |         |     |         |
| No                             | 99      | 40     | 0.60    | 18  | 0.28    | 46 | 0.19    |
| Yes                            | 71      | 32     |         | 8   | 0.30    | 40 | 0.13    |
| Pathologic T                   |         |        |         |     |         |     |         |
| pT0/pTis                       | 14      | 8      | 3       | 8   | 0.19    | 42 | 0.0002  |
| pT1                            | 26      | 5      | 0       | 7   | 0.015   | 38 | 0.044   |
| pT2                            | 75      | 29     | 8       | 38  | 0.0007  | 42 | 0.035   |
| pT3                            | 18      | 10     | 5       | 11  |          |     |         |
| pT4                            | 37      | 20     | 0.04    | 10  | 0.015   | 22 | 0.13    |
| Pathologic N                   |         |        |         |     |         |     |         |
| pN0                            | 20      | 3      | 2       | 3   | 0.0006  | 42 | 0.044   |
| pN1                            | 63      | 27     | 9       | 28  | 0.0002  | 42 | 0.035   |
| pN2                            | 52      | 26     | 12      | 33  |          |     |         |
| pN3                            | 35      | 16     | 0.026   | 3   | 0.12    | 22 | 0.044   |
| Stage                          |         |        |         |     |         |     |         |
| 0                              | 3       | 2      | 1       | 2   | 0.0006  | 42 | 0.035   |
| I                              | 6       | 0      | 0       | 0   | 0.0006  | 42 | 0.035   |
| IIa                            | 25      | 7      | 3       | 7   | 0.0006  | 42 | 0.035   |
| IIb                            | 25      | 9      | 4       | 9   | 0.0006  | 42 | 0.035   |
| IIIa                           | 43      | 20     | 6       | 27  | 0.0006  | 42 | 0.035   |
| IIIB                           | 39      | 18     | 8       | 21  | 0.0006  | 42 | 0.035   |
| IIIc                           | 29      | 16     | 0.049   | 4   | 0.76    | 20 | 0.044   |
| Histology                      |         |        |         |     |         |     |         |
| Ductal invasive                | 118     | 52     | 19      | 59  | 0.0006  | 42 | 0.035   |
| Lobular invasive               | 36      | 13     | 1       | 19  | 0.0006  | 42 | 0.035   |
| Others                         | 16      | 7      | 0.85    | 6   | 0.0006  | 42 | 0.035   |
| Pathologic skin involvement    |         |        |         |     |         |     |         |
| Absent                         | 136     | 56     | 16      | 67  | 0.0006  | 42 | 0.035   |
| Present                        | 34      | 16     | 0.78    | 10  | 0.0006  | 42 | 0.035   |
| LVI                            |         |        |         |     |         |     |         |
| Absent                         | 101     | 38     | 14      | 44  | 0.0006  | 42 | 0.035   |
| Present                        | 69      | 34     | 0.19    | 12  | 0.35    | 42 | 0.044   |
| Nuclear grading*               |         |        |         |     |         |     |         |
| G1                             | 11      | 4      | 0       | 5   | 0.0006  | 42 | 0.035   |
| G2                             | 54      | 17     | 3       | 25  | 0.0006  | 42 | 0.035   |
| G3                             | 80      | 40     | 0.18    | 16  | 0.0006  | 42 | 0.035   |
| Ki 67 index                    |         |        |         |     |         |     |         |
| < 20                           | 117     | 48     | 21      | 57  | 0.0006  | 42 | 0.035   |
| ≥ 20                           | 53      | 24     | 0.15    | 5   | 0.34    | 29 | 0.044   |
| ER status                      |         |        |         |     |         |     |         |
| Negative                       | 64      | 35     | 10      | 37  | 0.0006  | 42 | 0.035   |
| Positive                       | 106     | 37     | 0.015   | 16  | 0.99    | 49 | 0.20    |
| PgR status                     |         |        |         |     |         |     |         |
| Negative                       | 83      | 36     | 13      | 41  | 0.0006  | 42 | 0.035   |
| Positive                       | 87      | 36     | 0.83    | 13  | 0.87    | 45 | 0.83    |
| Extracapsular extension        |         |        |         |     |         |     |         |
| Absence                        | 115     | 37     | 13      | 48  | 0.0006  | 42 | 0.035   |
| Presence                       | 55      | 35     | 0.0007  | 13  | 0.035   | 38 | 0.035   |
our series disease downstaging and/or pCR to NAC were not independent prognostic factors for LRR occurrence.

In our experience PMRT was significantly protective only in case of clinical staged T3 tumors, regardless of response to NAC. Our results are consistent with the experience of M. D. Anderson Cancer Center, which in our knowledge represents the largest published series.

In a relevant study published in 2004, Huang et al. [7] showed how radiation was found to benefit both local control and survival for patients presenting with clinical T3 tumors or stage III-IV disease (ipsilateral SCV nodal) and for patients with four or more positive nodes.

In 2011, Nagar et al. [36] tried to determine the impact of PMRT after NAC on LRR in 162 patients with clinical T3N0 disease. PMRT was effective in reducing the LRR rate, even when there was no pathologic evidence of nodal involvement after NAC.

However we are aware of the limitations of our retrospective study: the two cohorts in the analyses had differences in several factors, and the more advanced tumor characteristics were in the PMRT group. PMRT may overcome negative pathologic features in the cohort.

A complex evaluation based on the presence of multiple risk factors should be of primary importance in the decision-making process for PMRT after NAC.

Fowble et al. [28] identified a cohort of women treated with NAC and mastectomy for whom PMRT may be omitted according to the projected risk of LRR. Seven breast cancer physicians from the University of California cancer centers created 14 hypothetical clinical case scenarios; an overall summary risk assessment table was developed, using the American College of Radiology rating scale. Clinical stage II (T1-2N0-1) patients, aged > 40 years, with ER positive subtype, with pCR or 0–3 positive nodes without LVI or ECE, were identified as having <10% risk of LRR without radiation.

Huang et al. [7, 14] retrospectively reviewed the hospital records of 542 patients treated on six consecutive institutional prospective trials using NAC and PMRT. In the multivariate analysis, skin/nipple involvement, SCV nodal involvement, no tamoxifen use, ECE, and ER negative were independently associated with developing LRR (HR 2.1–2.8; $P < 0.001–0.020$). The 10-year rate of LRR for patients with one or none of these factors was only 4%, but patients with two factors had a rate of 8%, and patients with three or more factors had a rate of 28% ($P < 0.0001$ for 0-1 factor versus 3–5 factors).

In order to validate the independent factors shown in the experience of the M. D. Anderson Cancer Center, we performed the same multiple factors analysis. Also in our series we found a significant higher LRR rate in patients with a greater number of risk factors (HR 2.70; 95% CI 1.12–6.53; $P = 0.023$; 54.3% LRR rate for patients with 3–5 factors).

The 2007 National Cancer Institute conference report recommended PMRT after NAC for patients presenting with clinical stage III disease or those with positive nodes after chemotherapy [37]. Our experience adds strength to the experiences that suggest PMRT after NAC based on clinical staging; however, we strongly believe that PMRT after NAC should be indicated following a comprehensive assessment of multiple factors.

### 5. Conclusions

Our experience confirmed the impact of pathological nodal involvement in patients’ outcome. After NAC and mastectomy, PMRT was found to benefit local control of patients presenting with clinical T3 tumors, regardless of the response to chemotherapy. Radiation should always be considered after a careful multidisciplinary assessment of multiple risk factors.
Table 5: Locoregional recurrence-free survival rate according to postmastectomy radiotherapy.

| Feature                          | N     | No PMRT | PMRT | LRR No PMRT | LRR PMRT | P value |
|----------------------------------|-------|---------|------|-------------|----------|---------|
| **Age groups**                   |       |         |      |             |          |         |
| ≤40                              | 33    | 18      | 15   | 5           | 1        | 0.13    |
| 41–50                            | 62    | 25      | 37   | 4           | 5        | 0.53    |
| 51–60                            | 5     | 18      | 32   | 3           | 6        | 0.62    |
| >60                              | 25    | 11      | 14   | 0           | 2        | 0.24    |
| **Clinical T**                   |       |         |      |             |          |         |
| T1                               | 4     | 2       | 2    | 0           | 0        | —       |
| T2                               | 52    | 26      | 24   | 3           | 0        | 0.12    |
| T3                               | 48    | 27      | 21   | 8           | 1        | **0.015**|
| T4                               | 66    | 15      | 51   | 1           | 13       | 0.15    |
| **Clinical N**                   |       |         |      |             |          |         |
| N0                               | 42    | 20      | 22   | 3           | 2        | 0.64    |
| N1                               | 95    | 45      | 90   | 7           | 4        | 0.15    |
| N2                               | 33    | 7       | 26   | 2           | 8        | 0.87    |
| **Multiple foci**                |       |         |      |             |          |         |
| No                               | 99    | 50      | 49   | 1           | 7        | 0.27    |
| Yes                              | 71    | 22      | 49   | 1           | 7        | 0.26    |
| **Pathologic T**                 |       |         |      |             |          |         |
| pTx/pTis                         | 14    | 7       | 7    | 2           | 1        | 0.29    |
| pT1                              | 26    | 13      | 13   | 0           | 0        | —       |
| pT2                              | 75    | 39      | 36   | 6           | 3        | 0.10    |
| pT3                              | 18    | 7       | 11   | 3           | 2        | 0.18    |
| pT4                              | 37    | 6       | 31   | 1           | 9        | 0.49    |
| **Pathologic N**                 |       |         |      |             |          |         |
| pN0                              | 20    | 14      | 6    | 2           | 0        | 0.35    |
| pN1                              | 63    | 29      | 34   | 3           | 6        | 0.62    |
| pN2                              | 52    | 16      | 36   | 5           | 7        | 0.16    |
| pN3                              | 35    | 13      | 22   | 2           | 1        | 0.54    |
| **Downstage**                    |       |         |      |             |          |         |
| No                               | 115   | 43      | 72   | 8           | 11       | 0.51    |
| Yes                              | 55    | 29      | 26   | 4           | 3        | 0.68    |
| **Histology**                    |       |         |      |             |          |         |
| Ductal invasive                  | 118   | 55      | 63   | 9           | 10       | 0.78    |
| Lobular invasive                 | 36    | 12      | 24   | 0           | 1        | 0.48    |
| Others                           | 16    | 5       | 11   | 3           | 3        | 0.17    |
| **Pathologic skin involvement**  |       |         |      |             |          |         |
| Absent                           | 136   | 66      | 70   | 11          | 5        | 0.061   |
| Present                          | 34    | 6       | 28   | 1           | 9        | 0.44    |
| **LVI**                          |       |         |      |             |          |         |
| Absent                           | 101   | 47      | 54   | 8           | 6        | 0.32    |
| Present                          | 69    | 25      | 44   | 4           | 8        | 0.93    |
| **Nuclear grading**             |       |         |      |             |          |         |
| G1                               | 11    | 6       | 5    | 0           | 0        | —       |
| G2                               | 54    | 26      | 28   | 3           | 0        | 0.06    |
| G3                               | 80    | 33      | 47   | 7           | 9        | 0.86    |
| **Ki 67 index**                  |       |         |      |             |          |         |
| < 20                             | 117   | 53      | 64   | 10          | 11       | 0.76    |
| ≥ 20                             | 53    | 19      | 34   | 2           | 3        | 0.69    |
Table 5: Continued.

| Feature                          | No PMRT | PMRT | LRR |
|---------------------------------|---------|------|-----|
|                                 | N       | No PMRT | PMRT | No PMRT | PMRT | P value |
| ER status                       |         |        |     |         |      |       |
| Negative                        | 64      | 30    | 34  | 4       | 6    | 0.81   |
| Positive                        | 106     | 42    | 64  | 8       | 8    | 0.32   |
| PgR status                      |         |        |     |         |      |       |
| Negative                        | 83      | 40    | 43  | 6       | 7    | 0.93   |
| Positive                        | 87      | 32    | 65  | 6       | 7    | 0.39   |
| Extracapsular extension         |         |        |     |         |      |       |
| Absence                         | 115     | 52    | 63  | 8       | 5    | 0.20   |
| Presence                        | 55      | 20    | 35  | 4       | 9    | 0.89   |
| NAC regimen                     |         |        |     |         |      |       |
| Anthracyclines-based            | 69      | 27    | 42  | 5       | 9    | 0.74   |
| Anthracyclines- and taxanes-based | 93   | 44    | 49  | 6       | 4    | 0.38   |
| No anthracyclines-based         | 8       | 1     | 7   | 1       | 1    | 0.008  |
| Adjuvant hormonal therapy       |         |        |     |         |      |       |
| No                             | 62      | 28    | 34  | 4       | 6    | 0.86   |
| Tamoxifen                       | 75      | 31    | 44  | 5       | 6    | 0.71   |
| AIs                            | 33      | 13    | 20  | 3       | 2    | 0.32   |
| Total                           | 170     | 72    | 98  | 12      | 14   |        |

*Some data are missing.
LRR: locoregional recurrence; PMRT: postmastectomy radiotherapy; LVI: lymph vascular invasion; ER: estrogen receptors; PgR: progesteron receptors; NAC: neoadjuvant chemotherapy; AIs: aromatase inhibitors.

Table 6: Main chemotherapy- and radiotherapy-related adverse events.

| Chemotherapy-related side effects | N   | %  |
|----------------------------------|-----|----|
| Anemia                           |     |    |
| Grades 0–2                       | 150 | 88 |
| Grades 3–5                       | 20  | 12 |
| Neutropenia                      |     |    |
| Grades 0–2                       | 142 | 83 |
| Grades 3–5                       | 28  | 17 |
| Piastrinopenia                   |     |    |
| Grades 0–2                       | 150 | 88 |
| Grades 3–5                       | 20  | 20 |
| Mucositis                        |     |    |
| Grades 0–2                       | 158 | 93 |
| Grades 3–5                       | 12  | 7  |
| Alopecia                         |     |    |
| Hypertransaminasemia             | 162 | 95 |
| Febrile neutropenia              | 15  | 9  |
| Radiotherapy-related side effects |     |    |
| Erythema                         | 32  | 33 |
| Thoracic wall pain               | 25  | 25 |
| Edema                            | 3   | 3  |
| Fatigue                          | 30  | 30 |
| Fibrosis                         | 20  | 20 |
| Telangiectasia                   | 8   | 8  |

PMRT group, any grades.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

All the authors contributed equally to this paper.

References

[1] J. S. D. Mieog, J. A. van der Hage, and C. J. H. van de Velde, “Neoadjuvant chemotherapy for operable breast cancer,” The British Journal of Surgery, vol. 94, no. 10, pp. 1189–1200, 2007.

[2] K. E. Hoffman, E. A. Mittendorf, and T. A. Buchholz, “Optimising radiation treatment decisions for patients who receive neoadjuvant chemotherapy and mastectomy,” The Lancet Oncology, vol. 13, no. 6, pp. e270–e276, 2012.

[3] M. E. Taylor, B. G. Haffty, R. Rabinovitch et al., “ACR appropriateness criteria on postmastectomy radiotherapy expert panel on radiation oncology-breast,” International Journal of Radiation Oncology Biology Physics, vol. 73, no. 4, pp. 997–1002, 2009.

[4] A. Goldhirsch, J. N. Ingle, R. D. Gelber, A. S. Coates, B. Thürlimann, and H.-J. Senn, “Thresholds for therapies: highlights of the St gallen international expert consensus on the primary therapy of early breast cancer 2009,” Annals of Oncology, vol. 20, no. 8, pp. 1319–1329, 2009.

[5] R. W. Carlson, D. C. Allred, B. O. Anderson et al., “Breast cancer. Clinical practice guidelines in oncology,” Journal of the National Comprehensive Cancer Network, vol. 7, no. 2, pp. 122–192, 2009.

However prospective trials in properly selected patients are strongly needed.
[6] National Institute for Health Clinical Excellence, *Early and Advanced Breast Cancer: Diagnosis and Treatment*, NICE Clinical Guideline no. 80, NICE, London, UK, 2009.

[7] E. H. Huang, S. L. Tucker, E. A. Strom et al., "Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy," *Journal of Clinical Oncology*, vol. 22, no. 23, pp. 4691–4699, 2004.

[8] N. Bouzubari, K. J. Walker, K. Griffiths et al., "Ki67 immunostaining in primary breast cancer: pathological and clinical associations," *The British Journal of Cancer*, vol. 59, no. 6, pp. 943–947, 1989.

[9] M. E. H. Hammond, D. F. Hayes, A. C. Wolff, P. B. Mangu, and S. Temin, "American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer," *Journal of Oncology Practice*, vol. 6, no. 4, pp. 195–197, 2010.

[10] I. Meattini, L. Livi, C. Saieva et al., "Prognostic role of human epidermal growth factor receptor 2 status in premenopausal early breast cancer treated with adjuvant tamoxifen," *Clinical Breast Cancer*, vol. 13, no. 4, pp. 247–253, 2013.

[11] L. Livi, I. Meattini, C. Saieva et al., "Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer," *Cancer*, vol. 118, no. 13, pp. 3236–3243, 2012.

[12] E. Munzone, E. Botteri, A. Sciamdivaschi et al., "Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer," *Breast Cancer Research and Treatment*, vol. 134, no. 1, pp. 277–282, 2012.

[13] M. Dowsett, T. O. Nielsen, R. A’Hern et al., "Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in breast cancer working group," *Journal of the National Cancer Institute*, vol. 103, no. 22, pp. 1656–1664, 2011.

[14] E. H. Huang, S. L. Tucker, E. A. Strom et al., "Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy," *International Journal of Radiation Oncology Biology Physics*, vol. 62, no. 2, pp. 351–357, 2005.

[15] M. Overgaard, P. S. Hansen, J. Overgaard et al., "Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy," *The New England Journal of Medicine*, vol. 337, no. 14, pp. 949–955, 1997.

[16] J. Ragaz, S. M. Jackson, N. Le et al., "Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer," *The New England Journal of Medicine*, vol. 337, no. 14, pp. 956–962, 1997.

[17] P. M. P. Poortmans, J. L. M. Venselaar, H. Struikmans et al., "The potential impact of treatment variations on the results of radiotherapy of the internal mammary lymph node chain: a quality-assurance report on the dummy run of EORTC phase III randomized trial 22922/10925 in stage I–III breast cancer," *International Journal of Radiation Oncology Biology Physics*, vol. 49, no. 5, pp. 1399–1408, 2001.

[18] J. L. Wright, C. Takita, I. M. Reis et al., "Predictors of locoregional outcome in patients receiving neoadjuvant chemotherapy and postmastectomy radiation," *Cancer*, vol. 119, no. 1, pp. 16–25, 2013.

[19] L. Livi, C. Saieva, B. Detti et al., "Loco-regional recurrence in 2064 patients with breast cancer treated with mastectomy without adjuvant radiotherapy," *European Journal of Surgical Oncology*, vol. 33, no. 8, pp. 977–981, 2007.

[20] E. A. Perez, V. J. Suman, N. E. Davidson et al., "Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the north central cancer treatment group N9831 intergroup adjuvant trial," *Journal of Clinical Oncology*, vol. 22, no. 18, pp. 3700–3704, 2004.

[21] E. Tan-Chiu, G. Yethers, E. Romond et al., "Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31," *Journal of Clinical Oncology*, vol. 23, no. 31, pp. 7811–7819, 2005.

[22] M. S. Ewer and J. A. O'Shaughnessy, "Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer," *Clinical Breast Cancer*, vol. 7, no. 8, pp. 600–607, 2007.

[23] M. L. Telli, S. A. Hunt, R. W. Carlson, and A. E. Guardino, "Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility," *Journal of Clinical Oncology*, vol. 25, no. 23, pp. 3525–3533, 2007.

[24] M. J. Piccart, J. Klijn, R. Paridaens et al., "Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European organization for research and treatment of cancer investigational drug branch for breast cancer," *Journal of Clinical Oncology*, vol. 15, no. 9, pp. 3149–3155, 1997.

[25] R. K. Ramanathan, V. V. Reddy, J. M. Holbert, and C. P. Belani, "Pulmonary infiltrates following administration of paclitaxel," *Chest*, vol. 110, no. 1, pp. 289–292, 1996.

[26] W. L. Read, J. E. Mortimer, and J. Picus, "Severe interstitial pneumonitis associated with docetaxel administration," *Cancer*, vol. 94, no. 3, pp. 847–853, 2002.

[27] S. E. McGuire, A. M. Gonzalez-Angulo, E. H. Huang et al., "Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy," *International Journal of Radiation Oncology Biology Physics*, vol. 68, no. 4, pp. 1004–1009, 2007.

[28] B. L. Fowble, J. P. Einck, D. N. Kim et al., "Role of postmastectomy radiation after neoadjuvant chemotherapy in stage II–III breast cancer," *International Journal of Radiation Oncology Biology Physics*, vol. 83, no. 2, pp. 494–503, 2012.

[29] J. L. Oh, M. J. Dryden, W. A. Woodward et al., "Locoregional control of clinically diagnosed multifocal or multicentric breast cancer after neoadjuvant chemotherapy and locoregional therapy," *Journal of Clinical Oncology*, vol. 24, no. 31, pp. 4971–4975, 2006.

[30] A. K. Garg, J. L. Oh, M. J. Oswald et al., "Effect of postmastectomy radiotherapy in patients <35 years old with stage II–III breast cancer treated with doxorubicin-based neoadjuvant chemotherapy and mastectomy," *International Journal of Radiation Oncology Biology Physics*, vol. 69, no. 5, pp. 1478–1483, 2007.

[31] M. E. Straver, E. J. T. Rutgers, S. Rodenhuis et al., "The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy," *Annals of Surgical Oncology*, vol. 17, no. 9, pp. 2411–2418, 2010.

[32] C. Liedtke, C. Mazouni, K. R. Hess et al., "Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer," *Journal of Clinical Oncology*, vol. 26, no. 8, pp. 1275–1281, 2008.

[33] R. Bhargava, S. Beriwal, D. J. Dabb et al., "Immunohistochemical surrogate markers of breast cancer molecular classes.
predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases,” *Cancer*, vol. 116, no. 6, pp. 1431–1439, 2010.

[34] W. F. Symmans, F. Peintinger, C. Hatzis et al., “Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy,” *Journal of Clinical Oncology*, vol. 25, no. 28, pp. 4414–4422, 2007.

[35] E. P. Mamounas, G. Tang, B. Fisher et al., “Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20,” *Journal of Clinical Oncology*, vol. 28, no. 10, pp. 1677–1683, 2010.

[36] H. Nagar, E. A. Mittendorf, E. A. Strom et al., “Local-regional recurrence with and without radiation therapy after neoadjuvant chemotherapy and mastectomy for clinically staged T3N0 breast cancer,” *International Journal of Radiation Oncology Biology Physics*, vol. 81, no. 3, pp. 782–787, 2011.

[37] T. A. Buchholz, C. D. Lehman, J. R. Harris et al., “Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a national cancer institute conference,” *Journal of Clinical Oncology*, vol. 26, no. 5, pp. 791–797, 2008.